<p>Acute myocardial infarction (AMI) is myocardial necrosis resulting from acute obstruction of a coronary artery. Symptoms include chest discomfort with or without dyspnea, nausea, and/or diaphoresis. Diagnosis is by electrocardiography (ECG) and the presence or absence of serologic markers. Treatment is antiplatelet drugs, anticoagulants, nitrates, beta-blockers, statins, and reperfusion therapy. For ST-segment-elevation myocardial infarction, emergency reperfusion is via fibrinolytic drugs, percutaneous intervention, or, occasionally, coronary artery bypass graft surgery. For non-ST-segment-elevation myocardial infarction, reperfusion is via percutaneous intervention or coronary artery bypass graft surgery.</p>
<p>&nbsp;</p>
<p>Acute Myocardial Infarction is one of the leading causes of death in the developed world. Acute Myocardial Infarction can be divided into two categories, non-ST-segment elevation MI (NSTEMI) and ST-segment elevation MI (STEMI). Unstable angina is similar to NSTEMI. However, cardiac markers are not elevated.</p>
<h2><strong>Acute Myocardial Infarction Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Acute Myocardial Infarction in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Total Incident Cases</li>
<li>Type-specific Incident Cases</li>
<li>Gender-specific Incident Cases&nbsp;</li>
</ul>
<h2><strong>Acute Myocardial Infarction Epidemiology</strong></h2>
<ul>
<li>The total incident cases of Acute Myocardial Infarction in the United States is estimated to be ~822,800 in 2023. The cases are expected to increase by 2034.</li>
<li>There were ~45,700 cases of STEMI and ~34,500 cases of NSTEMI in Japan in 2023.</li>
<li>In EU4 and the UK, the incident cases of Acute Myocardial Infarction were ~930,900 cases in males and ~537,500 cases in females in 2023.</li>
</ul>
<h2><span style="text-decoration: underline;"><a href="https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market"><strong>Acute Myocardial Infarction Market</strong></a></span></h2>
<p>The Acute Myocardial Infarction market size in the 7MM was around USD 1,600 million in 2023.</p>
<h2>Acute Myocardial Infarction Market Drivers:</h2>
<ul>
<li>Growing awareness of heart disease and the importance of timely intervention in preventing complications.</li>
<li>Advancements in diagnostic techniques, including improved imaging and biomarkers for early detection of heart attacks.</li>
<li>Increased availability and adoption of innovative treatments, such as thrombolytic therapies, percutaneous coronary interventions, and stent technology.</li>
<li>Rising demand for personalized treatment approaches based on genetic and biomarker data for better patient outcomes.</li>
<li>Strengthened patient education and preventative measures, leading to earlier recognition and better management of risk factors.</li>
</ul>
<h2>Acute Myocardial Infarction Market Barriers:</h2>
<ul>
<li>High treatment costs, particularly for advanced therapies, surgeries, and prolonged hospital stays.</li>
<li>Delays in diagnosis and treatment, often due to lack of awareness or recognition of symptoms by patients or healthcare providers.</li>
<li>Limited access to specialized care, especially in low-income or rural areas with fewer cardiology experts and facilities.</li>
<li>Risk of recurrence and long-term complications, which can complicate treatment plans and reduce quality of life.</li>
<li>Regulatory challenges and slow approval processes for new drug therapies or medical devices aimed at improving patient outcomes.</li>
</ul>
<h2><strong>Acute Myocardial Infarction Emerging Drugs</strong></h2>
<p>The emerging drugs of the Acute Myocardial Infarction market are</p>
<ul>
<li>Selatogrel (ACT-246475)</li>
<li>Dutogliptin</li>
<li>FARXIGA/FORXIGA (dapagliflozin)</li>
<li>FDY-5301</li>
<li>Zalunfiban (RUC 4)</li>
<li>Ziltivekimab</li>
<li>Milvexian</li>
<li>ProtheraCytes</li>
<li>KAND567</li>
<li>Olpasiran (AMG 890)</li>
</ul>
<p>And others.</p>
<h2><strong>Acute Myocardial Infarction Key Players</strong></h2>
<p>The key players in the Acute Myocardial Infarction market are</p>
<ul>
<li>Idorsia Pharmaceuticals</li>
<li>Viatris</li>
<li>Recardio</li>
<li>AstraZeneca</li>
<li>Faraday Pharmaceuticals</li>
<li>CeleCor Therapeutics</li>
<li>Novo Nordisk</li>
<li>Bristol Myers Squibb</li>
<li>Johnson &amp; Johnson Innovative Medicine</li>
<li>CellProthera</li>
<li>BioCardia</li>
<li>Kancera</li>
<li>Amgen</li>
<li>Arrowhead Pharmaceuticals</li>
</ul>
<p>And others.</p>

Acute Myocardial Infarction Market Infographic

Acute Myocardial Infarction Market

Acute Myocardial Infarction Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.